Sodium iodopyrupate, 123-I (Natrii iodohyppuras [123I])

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Radiopaque means

Included in the formulation
  • Sodium o-iodoppyrate, 123-I
    solution in / in 
    Federal State Unitary Enterprise "Federal Center for Design and Development of Nuclear Medicine Facilities" FMBA of Russia     Russia
  • Sodium o-iodoppyrate, 123-I
    solution in / in 
    Radium Institute. VGKhlopina NGO, State Unitary Enterprise     Russia
    • АТХ:

    V.09.C.X   Other radiopharmaceuticals for the detection of kidney diseases

    Pharmacodynamics:

    It is based on the elimination of radioactive iodine (123I: half-life - 13.2 hours; the decay constant is 0.0533 h-1; type of decay - electron capture; emitted radiation: γ-radiation with an energy of 159 kev; mean number of emissions / decay - 0.83) by tubular secretion and glomerular filtration, which can be visualized and measured using the appropriate equipment. Radiopharmaceutical preparation for the study of kidney pathology and obstruction of the urinary tract. The maximum accumulation of the drug in the kidneys is normally recorded in 2-3 minutes and is about 20%.

    Pharmacokinetics:

    The half-life is 20-30 minutes. The maximum concentration in the kidneys is ~ 3-6 minutes. Elimination by the kidneys (50-75% for 25 minutes, 90-95% for 8 hours, mainly by tubular secretion, but also by glomerular filtration). 123I also excreted in breast milk.

    Indications:

    Radioisotope study of kidney and urinary tract:

    - determination of effective renal blood flow;

    - study of total and separate secretory and excretory capacity of the kidneys and urodynamics of the upper and lower urinary tract;

    - assessment of anatomical features and topographic examination of the kidneys and urinary tract;

    - the detection of violations of the kidneys and urinary tract;

    - determination of the degree of these disorders in various diseases.

    ICD-10

    XXI.Z00-Z13.Z03   Medical surveillance and evaluation in case of suspected disease or pathological condition

    Contraindications:

    Severe leukopenia, bPregnancy and breastfeeding.

    Carefully:No data.
    Pregnancy and lactation:

    FDA recommendation category C. It is necessary to exclude the possibility of pregnancy in women of childbearing age. In situations where the expected benefits for the patient and fetus outweigh the potential risk of fetal exposure, it is necessary to reduce the dose of the radiopharmaceutical to the lowest possible.

    Dosing and Administration:

    Renography: intravenously 3.7-14.8 MBq (100-400 μCi).

    Radiography is performed within 15-20 minutes after administration, information is recorded using four sensors located in the projection of the heart, both kidneys and the bladder.

    Scintigraphy of the kidneys (to assess the size, position, configuration and function of the kidneys): intravenously 37 MBq (1 mCi) or 0.55 MBq / kg.

    The results are recorded in the sitting position with the back to the γ-chamber detector.

    Side effects:

    Digestive system: nausea or vomiting.

    Leather: skin itch, skin rashes.

    Fainting.

    Overdose:

    Overdose is not described. Treatment is symptomatic.

    Interaction:

    When used simultaneously with probenecid it is possible to reduce the accumulation of sodium [123I] yodohippurata in the kidneys due to the inhibition of enzyme transport systems of the proximal renal tubules.

    Special instructions:No data.
    Instructions
    Up